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Chemical reactions of MPDP+, a recognized intermediate in the metabolic conversion of the neurotoxin 
MPTP by monoamine oxidase B into its major metabolite MPP+, were studied.Addition of cyanide to 
MPDP+ bromide in aqueous solutions afforded cyano-compound 5 which isomerized in the presence of sili- 
ca gel into compound 6. Both 5 and 6 when heated yielded a third isomer 7. MPDP+ bromide disproportio- 
nated into MPTP and MPP+ in aqueous solution near neutral or slightly alkaline pH, a reaction which 
also occurred when MPDP+ bromide was treated with an amine in dichloromethane solution. Disproportio- 
nation of MPDP+ at physiological pH may be of biochemical significance, since formation of MPP+ from 
MPDP+ can occur non-enzymatically. MPTP, MPDP+, and MPP+ inhibited dopamine uptake in rat synap- 
tosomal preparations with I,, values of 30, 37, and 3.4 PM, respectively. The competition of these com- 
pounds with dopamine for uptake sites in the membrane may contribute in part to the reduced levels of 
dopamine observed in animals treated with MPTP. 
MAO oxidation Neurotoxin MPTP Metabolism Dihydropyridine Dopamine uptake 
1. INTRODUCTION 
The nigrostriatal toxin I-methyl-4-phenyl- 
1,2,3,6_tetrahydropyridine (MPTP, 1) [l-4] is 
converted in vivo by brain tissue [5], and in vitro 
by monkey brain homogenates [6] and rat brain 
mitochondrial incubation mixtures [7,8] into the 
1-methyl-4-phenylpyridinium species (MPP+, 3), a 
major metabolite of MPTP in primates which ac- 
cumulates in brain tissue [5]. It was found [7,9-l I] 
that pargyline and other MAO-B inhibitors block 
this conversion of MPTP, suggesting that oxida- 
tion of MPTP is catalysed by this enzyme. The 
hypothesis that I-methyl-4-phenyl-2,3-dihydropy- 
ridinium species (MPDP+, 2) is an intermediate in 
the metabolic conversion of MPTP into MPP+ 
[4,7] was recently proved in experiments with 
7 Visiting Scientist from A. Mickiewicz University, POZ- 
nan, Poland 
purified MAO-B from human [ 121 and bovine liver 
[12,13]. Formation of MPDP+ was also demon- 
strated indirectly by cyanide addition, to trap reac- 
tive intermediates formed by incubation of MPTP 
with mouse liver microsomal preparations. Gas 
chromatography-mass spectrometry (GC-MS) 
showed in this case the presence of 3 different 
cyano-compounds [141. 
2. MATERIALS AND METHODS 
Rat striatal synaptosomes were prepared by the 
method of Gray and Whittaker [ 151 and suspended 
in a medium containing 50 mM Tris-HCI (pH 7.4), 
125 mM NaCl, 5 mM KCl, 1 mM CaC12, 1 mM 
MgC12, and 10 mM glucose (physiological Tris). 
An incubation mixture containing test compound, 
[‘4C]dopamine (0.89 PM, spec. act. 0.5 &i/ 
cmol), 0.02% ascorbic acid, and 0.125 mM niala- 
mide in physiological Tris was prewarmed at 37°C 
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for 5 min. [14C]Dopamine uptake was initiated by 
addition of the freshly prepared synaptosomes 
(-0.2 mg Pz-protein) and the reaction mixture 
(total volume 1 ml) incubated at 37°C for 5 min. 
The reaction was stopped by chilling the incuba- 
tion tubes in ice-water and the synaptosomes re- 
covered by membrane filtration (Millipore HAWP, 
0.45 pm). After washing the filters twice with ice- 
cold physiological Tris (5 ml each time), the radio- 
activity retained on the filters was determined by a 
Beckman LS 6800 Scintillation System in 7.5 ml 
Hydrocount (Baker). A parallel [‘4C]dopamine up- 
take study at 0°C (ice bath) was carried out for 
each compound and the values subtracted from 
those obtained at 37°C. The net value represents 
the amount of specific [14C]dopamine uptake. The 
percent inhibition of [‘4C]dopamine uptake by the 
test compound was calculated and plotted over at 
least 6 different concentrations. The concen- 
tration that inhibits 50% of the synaptosomal 
[‘4C]dopamine uptake is expressed as the ZSO value. 
MPTP was purchased as the free base from 
Aldrich, Milwaukee, WS. MPDP+ (2) as bromide 
salt was obtained as described [12]. Addition of 
cyanide to MPDP+ was performed as described by 
Gierson et al. [ 161. Melting points were determined 
on a Fisher-Johns apparatus and are corrected. ‘H- 
NMR spectra were recorded using a Varian 
HR-220 or Varian XL-300 spectrometer with TMS 
as internal standard. Electron impact mass spectra 
(EIMS) were obtained on a VG-Micromass 7070 F 
spectrometer with a DS 2050 data system. UV 
spectra were measured with a Hewlett-Packard 
8450A UV-VIS spectrometer. TLC plates were 
purchased from Analtech, Newark, DE and silica 
gel 60 (15-40pm) was from Merck, Darmstadt, 
FRG. 
3. RESULTS 
Addition of cyanide to MPDP+ bromide (2) in 
a two-phase system of dichloromethane-water [ 161 
gave cyano-compound 5 (171, which isomerized in 
dichloromethane solution when passed through a 
silica gel column into the new isomer 6. Cyano- 
compounds 5 and 6 were indistinguishable on 
TLC. The new isomer 6 had the following 
characteristics: m.p. 91-92°C (from isopropyl 
ether); EIMS, m/z 198 (M+); ‘H-NMR S 7.32, 
6.11, 3.99, 3.45, 3.10, 2.73 and 2.50; UV (MeOH) 
346 
h max 245 nm (6 = 14600). While cyano-compound 
5 afforded 2 with perchloric acid [8], cyano- 
compound 6 is stable to acid at room temperature, 
but is converted, like 5, upon heating to 150°C to 
isomer 7, with the C = C double bond conjugated 
to the carbon atom bearing the cyano-substituent. 
Isomer 7, obtained as an oil, showed the following 
characteristics: EIMS, m/z 198 (M+); ‘H-NMR 
(CdCl3) 6 7.26, 5.43, 3.57, 2.98, 2.86, 2.14 and 
1.88; UV (MeOH) X,,, 275 nm (f = 6700). 
A solution of MPDP+ bromide (2) in water (pH 
5.0), when adjusted in argon atmosphere to pH 7 
with sodium bicarbonate solution quantitatively 
gave 1 and 3 by disproportionation. This reaction 
could easily be followed by UV spectroscopy and 
a shift of the UV maximum from 343 nm to 
293 nm characteristic for 3 in water [12]. 
The reaction mixture obtained by dispropor- 
tionating 250 mg MPDP+ bromide (2) in water af- 
forded 76 mg MPTP (1) and 118 mg MPP+ iodide 
(3), isolated from the aqueous phase after removal 
of MPTP with ether, adjusting the pH to 10 with 
sodium hydroxide, addition of sodium iodide and 
extraction with a mixture of dichloromethane- 
isopropanol (4 : 1). 
Disproportionation also occurred when 2 was 
treated with diethylamine, triethylamine, or ,&- 
(3,4-dimethoxyphenyl)ethylamine in dichloro- 
methane solution at 0°C. MPDP+ bromide (2) did 
not react with dopamine in aqueous solutions over 
a wide pH range (5.0-7.6) since no formation of 
new catecholic products could be detected on TLC. 
The effects of MPTP and its metabolites on 
Table 1 
Inhibition of synaptosomal dopamine uptake by MPTP, 
MPDP+ and MPP+ 
Compound Zso (uM) 
1-Methyl-Cphenyl-1,2,3,6- 
tetrahydropyridine (MPTP) 30 
1-Methyl-4-phenyl-2,3-dihydro- 
pyridinium bromide (MPDP+) 37 
1-Methyl-4-phenylpyridinium 
bromide (MPP+) 3.4 
At least 6 different concentrations of each compound 
were tested for inhibition of [14C]dopamine uptake into 
synaptosomes as described in the text 
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dopamine uptake in synaptosomal preparations 
are shown in table 1. MPTP and MPDP+ blocked 
dopamine uptake in the 10m5 M range. MPP+ was 
the most effective compound with an ISO value of 
3.4 PM. In comparison, nomifensine, a potent in- 
hibitor of dopamine re-uptake into presynaptic 
neuronal terminals [ 181, gave an 40 value of 
0.1 PM. 
4. DISCUSSION 
Results of studies with the neurotoxin MPTP 
(1)s which depletes the substantia nigra of 
dopamine, and causes toxic symptoms similar to 
those observed in Parkinson’s disease in man, sug- 
gest that consequences of its metabolism are com- 
plex. The findings reported here, and corroborated 
by data obtained elsewhere, suggest that MPP+ 
(3), a major metabolite found in the nigrostriatum 
of man and animals after exposure to MPTP, 
originates from the precursor MPDP+ (2) or its 
dienamine tautomer. MPDP+ is formed in vivo in 
an oxidation reaction catalyzed by MAO-B 
[12,13]. A study of the chemical reactivity of 
MPDP+ and MPP+ under physiological condi- 
tions seems, therefore, of paramount importance. 
Data presented here show that the addition of 
cyanide, intended to trap the chemically reactive 
MPDP+ [14] affords cyano-compounds 5 and 6 
depending on reaction conditions. Cyano- 
compound 5 is converted into isomer 6 when ex- 
posed in dichloromethane solution to silica gel, 
and both 5 and 6 are converted into the ther- 
modynamically most stable isomer 7 when heated 
to 150°C. Formation of 6 from 5 was not in- 
vestigated in detail, and is assumed to have 
originated by abstraction of hydrogen cyanide 
from 5 and addition to the discretely formed im- 
inium species 4 or its dienamine tautomer. The 
finding that MPDP+ did not react with dopamine 
under physiological conditions makes it unlikely 
that MPDP+ traps biogenic amines to cause an im- 
balance in amine levels, as has been suggested 
14371. 
The observed disproportionation of MPDP+ in- 
to MPTP and MPP+ at physiological pH, also 
observed by Castagnoli et al. [8], and not affected 
in brain mitochondrial incubation mixtures when 
pargyline was added [8], supports the idea that 
physiological factors may favor disproportiona- 
1+3 
A 
1 2 
7 
Fig. 1. 
tion of MPDP+. It should be noted that MPTP 
(l), a tertiary amine, is able to cross membranes 
and thus infiltrate neighboring neurons, undergo- 
ing there the same reaction cycles. MPP+, on the 
other hand, is a quaternary species, which pro- 
bably remains in neurons of origin until it is fur- 
ther metabolized; by doing so, however, it may 
block their functioning as suggested by Markey et 
al. [5]. MPP+ is acutely more toxic than MPTP to 
mice after i-p. administration [19], and identifica- 
tion of its biological targets may be directly related 
to the development of Parkinson-like symptoms in 
animal and man. In this regard, it is of interest to 
note that Javitch and Snyder [20] recently found 
that MPP+, but not MPTP, accumulates through 
the dopamine neuronal uptake system. 
Our finding that MPP+, and to a lesser extent 
MPDP+ and MPTP, inhibit dopamine uptake in 
synaptosomal preparations is consistent with 
347 
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previous studies which show that MPTP inhibits 
dopamine uptake in synaptosomes from several 
species [21], and cultured rat pheochromocytoma 
cells [22]. Our finding that MPP+, the product 
which accumulates in the substantia nigra, is the 
most potent derivative tested, may explain in part 
the reduced levels of dopamine in the 
nigrostriatum following MPTP administration. 
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